BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Aclara developed microfluidic lab-on-a-chip technology with applications for genomics, high-throughput drug screening and clinical diagnostics. The company’s technology substantially enlarged throughput capacity while dramatically lowering costs compared with competing approaches. The cornerstone of Aclara’s product development strategy was a disposable plastic or glass “chip” called a LabCard that enabled the computerized control of the movement, measurement and mixing of liquids without the use of moving parts or valves.
Aclara Biosciences
Mountain View, CA
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.